UY27027A1 - Kit de repinotano - Google Patents

Kit de repinotano

Info

Publication number
UY27027A1
UY27027A1 UY27027A UY27027A UY27027A1 UY 27027 A1 UY27027 A1 UY 27027A1 UY 27027 A UY27027 A UY 27027A UY 27027 A UY27027 A UY 27027A UY 27027 A1 UY27027 A1 UY 27027A1
Authority
UY
Uruguay
Prior art keywords
repinothane
kit
repinotane
salt
physiologically harmless
Prior art date
Application number
UY27027A
Other languages
English (en)
Inventor
Dr Werner Kroll
Dr Ferdinant Rombout
Dr Horst Weber
Dr Maria Luisa Rodriguez
Dr Bernd Sennhenn
Dr Rudolf Schohe-Loop
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of UY27027A1 publication Critical patent/UY27027A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La invención trata de kit que incluye una composición farmacéutica, que contiene repinotano o una sal fisiológicamente inofensiva de repinotano, y un medio para determinar la concentración de repinotano o sus metabolitos en líquidos corporales, así como nuevas composiciones farmacéuticas, que contienen repinotano o una sal fisiológicamente inofensiva de repinotano, y procedimientos para la preparación de éstos.
UY27027A 2000-11-22 2001-11-19 Kit de repinotano UY27027A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10058119A DE10058119A1 (de) 2000-11-22 2000-11-22 Pepinotan-Kit

Publications (1)

Publication Number Publication Date
UY27027A1 true UY27027A1 (es) 2002-07-31

Family

ID=7664358

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27027A UY27027A1 (es) 2000-11-22 2001-11-19 Kit de repinotano

Country Status (37)

Country Link
US (2) US6605255B2 (es)
EP (1) EP1339403B1 (es)
JP (2) JP2004517824A (es)
KR (1) KR20030096237A (es)
CN (2) CN1715279A (es)
AR (1) AR031761A1 (es)
AT (1) ATE284212T1 (es)
AU (1) AU2002227912A1 (es)
BG (1) BG107803A (es)
BR (1) BR0115518A (es)
CA (1) CA2429310A1 (es)
CZ (1) CZ20031401A3 (es)
DE (2) DE10058119A1 (es)
DO (1) DOP2001000293A (es)
EC (1) ECSP034617A (es)
EE (1) EE200300242A (es)
ES (1) ES2234922T3 (es)
GT (1) GT200100236A (es)
HN (1) HN2001000262A (es)
HR (1) HRP20030490A2 (es)
HU (1) HUP0303294A2 (es)
IL (1) IL155975A0 (es)
MA (1) MA26059A1 (es)
MX (1) MXPA03004499A (es)
MY (1) MY118345A (es)
NO (1) NO20032212D0 (es)
NZ (1) NZ525964A (es)
PE (1) PE20020533A1 (es)
PL (1) PL361628A1 (es)
PT (1) PT1339403E (es)
RU (1) RU2003118583A (es)
SI (1) SI1339403T1 (es)
SK (1) SK5922003A3 (es)
SV (1) SV2003000744A (es)
UY (1) UY27027A1 (es)
WO (1) WO2002041881A2 (es)
ZA (1) ZA200303888B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004010050A1 (de) * 2004-03-02 2005-09-22 Bayer Healthcare Ag Spezifische monoklonale und polyklonale Antikörper für Repinotan und dessen ringoffene Form
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
JP5261487B2 (ja) * 2007-08-03 2013-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン誘導体の結晶形
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
JP2016525532A (ja) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄異形成症候群の処置
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901814A1 (de) 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE19522088A1 (de) * 1995-06-19 1997-01-02 Bayer Ag Benzisothiazolyl-substituierte Aminomethylchromane
DE19543476A1 (de) * 1995-11-22 1997-05-28 Troponwerke Gmbh & Co Kg Verwendung von substituierten Aminomethyl-chromanen zur Behandlung von Schädel-Hirn-Trauma
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
DE19754573A1 (de) * 1997-12-09 1999-06-10 Bayer Ag Pharmazeutische Zusammensetzung zur Behandlung von Schlaganfall und Schädel-Hirn-Trauma
AU757405B2 (en) * 1998-03-10 2003-02-20 Bayer Aktiengesellschaft Integrated assay device and methods of production and use
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19936281C2 (de) 1999-08-02 2002-04-04 Bayer Ag Verfahren zur Gefriertrocknung

Also Published As

Publication number Publication date
SV2003000744A (es) 2003-01-13
CZ20031401A3 (cs) 2003-10-15
PT1339403E (pt) 2005-03-31
EP1339403B1 (de) 2004-12-08
EE200300242A (et) 2003-10-15
HN2001000262A (es) 2002-01-30
ATE284212T1 (de) 2004-12-15
AR031761A1 (es) 2003-10-01
PE20020533A1 (es) 2002-07-13
NO20032212L (no) 2003-05-15
NO20032212D0 (no) 2003-05-15
CA2429310A1 (en) 2002-05-30
ECSP034617A (es) 2003-06-25
WO2002041881A2 (de) 2002-05-30
CN1715279A (zh) 2006-01-04
US20030060493A1 (en) 2003-03-27
JP2004517824A (ja) 2004-06-17
PL361628A1 (en) 2004-10-04
KR20030096237A (ko) 2003-12-24
DE10058119A1 (de) 2002-05-23
ZA200303888B (en) 2004-05-20
BR0115518A (pt) 2003-09-16
DOP2001000293A (es) 2002-03-15
MA26059A1 (fr) 2004-04-01
MXPA03004499A (es) 2004-05-14
AU2002227912A1 (en) 2002-06-03
CN1518446A (zh) 2004-08-04
JP2005232189A (ja) 2005-09-02
DE50104790D1 (de) 2005-01-13
HUP0303294A2 (en) 2007-09-28
RU2003118583A (ru) 2004-12-20
WO2002041881A3 (de) 2002-10-10
MY118345A (en) 2004-10-30
BG107803A (bg) 2004-01-30
ES2234922T3 (es) 2005-07-01
HRP20030490A2 (hr) 2005-06-30
SI1339403T1 (en) 2005-04-30
NZ525964A (en) 2006-02-24
US6605255B2 (en) 2003-08-12
GT200100236A (es) 2002-06-25
IL155975A0 (en) 2003-12-23
SK5922003A3 (en) 2003-11-04
US20030203953A1 (en) 2003-10-30
EP1339403A2 (de) 2003-09-03

Similar Documents

Publication Publication Date Title
UY27027A1 (es) Kit de repinotano
UY28348A1 (es) Compuestos novedosos
CR8257A (es) Construcciones de union y metodos para uso de ellas
UY28342A1 (es) Nuevos compuestos
NI200600290A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
CY1111579T1 (el) Νεα συνδυασμενη χρηση μιας ενωσης σουλφοναμιδης (sulfonamide) στην θεραπεια του καρκινου
UY27080A1 (es) Nuevas imidazotriazinonas sustituídas
BRPI0609711B8 (pt) uso de uma solução aquosa com potencial redutivo oxidativo (orp)
AR030185A1 (es) Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialmente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologicas
SV2006002174A (es) Composicion de anticuerpo her2
BRPI0412029A (pt) formulações para microprojeções revestidas contendo contra-ìons não-voláteis
CR8717A (es) Nuevos compuestos
DE60106954D1 (de) Resorcin-derivate
ECSP078057A (es) Formulaciones de estrógenos conjugados y bazedoxifeno
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
GT200000077A (es) Sal mutua de amlodipino y atorvastatina
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
SE0302546D0 (sv) New compounds
ECSP055998A (es) Composición farmacéutica que comprende ácido 5-metil-2-2'-(cloro-6'-fluoroanilino)fenilacético
BRPI0514258A (pt) composições e sistemas para uso na cavidade bucal
CR8443A (es) Pirazolopirimidinas
BR0318659A (pt) derivados de prolina usados como ingredientes farmacêuticos ativos no tratamento de tumores
BR0009194A (pt) Composição do resorcinol
ATE418613T1 (de) Antimikrobielle zusammensetzungen

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141105